ReNeuron Group is a UK biotech company developing allogeneic cell therapies. Human retinal progenitor cells are the lead Phase I/IIa project for retinitis pigmentosa. There is a strong preclinical technology base in exosomes and cell therapies.
More ReNeuron Group content >Investment summary
ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. The company expects to report some data by March 2022, which could potentially open the way to a crucial partnering deal. Full efficacy data at six months post-treatment should be available around the middle of 2022. Our valuation remains £190m.
Y/E Mar |
Revenue (£m) |
EBITDA (£m) |
PBT (£m) |
EPS (p) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 6.2 | (14.0) | (13.9) | (35.85) | N/A | N/A |
| 2021A | 0.3 | (12.5) | (13.4) | (29.00) | N/A | N/A |
| 2022E | 0.3 | (12.8) | (13.1) | (19.12) | N/A | N/A |
| 2023E | 0.4 | (12.8) | (13.2) | (19.12) | N/A | N/A |
Content on ReNeuron Group
ReNeuron Group – Extension trial to produce data in Q122
Healthcare
|
research Update
|
8 October 2021
ReNeuron Group – Extension trial back on track but with data delay
Healthcare
|
research Update
|
15 July 2021
ReNeuron Group – Short delay to hRP trial, data now likely in Q421
Healthcare
|
research Update
|
18 June 2021
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (£m) | 11 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| John Berriman | Chairman |
| Olav Hellebø | CEO |
| Michael Hunt | CFO |
| John Sinden | Chief Scientific Officer |